Alan .k

Biography

Alan Kane has support Sigmoid in a number of roles since 2007 including as member of the Board of Directors, Finance Director, and most recently as Company Secretary. He is also Managing Director of Sentinel Investments (Shannon) Limited, a privately owned Irish company, established in June 1988 and licensed by the Irish Government to trade in a wide range of financial services. The core elements of Sentinel’s business are Structured Finance, Company Management Services and Portfolio Management. In the initial phase of his career Alan qualified as a Chartered Secretary and subsequently trained as an accountant with PriceWaterhouse in Dublin. SmPill® is the main focus of Sigmoid’s current development work and underpins all product development programmes. CyCol®, Sigmoid’s lead clinical development program, which is advancing into Phase 3 trials for moderate to severe ulcerative colitis, was uniquely enabled using SmPill® drug delivery technology.

Research Interest

SmPill® is the main focus of Sigmoid’s current development work and underpins all product development programmes. CyCol®, Sigmoid’s lead clinical development program, which is advancing into Phase 3 trials for moderate to severe ulcerative colitis, was uniquely enabled using SmPill® drug delivery technology.